Detailed Information

Cited 8 time in webofscience Cited 0 time in scopus
Metadata Downloads

Comparison of diagnostic sensitivity of [F-18]fluoroestradiol and [F-18]fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast canceropen access

Authors
Chae, Sun YoungSon, Hye JooLee, Dong YunShin, EonwooOh, Jungsu S.Seo, Seung YeonBaek, SoraKim, Ji YoungNa, Sae JungMoon, Dae Hyuk
Issue Date
May-2020
Publisher
SPRINGER
Keywords
Breast cancer; Estrogen receptor; [F-18]FES PET; CT; [F-18]FDG PET; CT
Citation
EJNMMI RESEARCH, v.10, no.1, pp.1 - 9
Indexed
SCIE
SCOPUS
Journal Title
EJNMMI RESEARCH
Volume
10
Number
1
Start Page
1
End Page
9
URI
https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/145809
DOI
10.1186/s13550-020-00643-z
ISSN
2191-219X
Abstract
Background To compare the diagnostic sensitivity of [18F]fluoroestradiol ([18F]FES) and [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) for breast cancer recurrence in patients with estrogen receptor (ER)-positive primary breast cancer. Methods Our database of consecutive patients enrolled in a previous prospective cohort study to assess [18F]FES PET/CT was reviewed to identify eligible patients who had ER-positive primary breast cancer with suspected first recurrence at presentation and who underwent [18F]FDG PET/CT. The sensitivity of qualitative [18F]FES and [18F]FDG PET/CT interpretations was assessed, comparing them with histological diagnoses. Results Of the 46 enrolled patients, 45 were confirmed as having recurrent breast cancer, while one was diagnosed with chronic granulomatous inflammation. Forty (89%) patients were ER-positive, four (9%) were ER-negative, and one (2%) patient did not undergo an ER assay. The sensitivity of [18F]FES PET/CT was 71.1% (32/45, 95% CI, 55.7–83.6), while that of [18F]FDG PET/CT was 80.0% (36/45, 95% CI, 65.4–90.4) with a threshold of positive interpretation, and 93.3% (42/45, 95% CI, 81.7–98.6) when a threshold of equivocal was used. There was no significant difference in sensitivity between [18F]FES and [18F]FDG PET/CT (P = 0.48) with a threshold of positive [18F]FDG uptake, but the sensitivity of [18F]FDG was significantly higher than [18F]FES (P = 0.013) with a threshold of equivocal [18F]FDG uptake. One patient with a benign lesion showed negative [18F]FES but positive [18F]FDG uptake. Conclusions The restaging of patients who had ER-positive primary breast cancer and present with recurrent disease may include [18F]FES PET/CT as an initial test when standard imaging studies are equivocal or suspicious.
Files in This Item
Appears in
Collections
서울 의과대학 > 서울 핵의학교실 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Ji Young photo

Kim, Ji Young
COLLEGE OF MEDICINE (DEPARTMENT OF NUCLEAR MEDICINE)
Read more

Altmetrics

Total Views & Downloads

BROWSE